> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Fresenius Recalls Morphine Injection Syringe Lot Due to Labeling Mix-Up
- URL: https://www.fdaweb.com/fresenius-recalls-morphine-injection-syringe-lot-due-to-labeling-mix-up/
- Published: 2026-08-05T12:00:00.000Z
- Updated: 2026-09-14T13:44:30.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5161584

Fresenius Kabi is recalling (Class 1) one lot of Simplist (morphine sulfate injection USP) 2 mg/1 mL prefilled syringes after discovering a labeling mix-up that could result in patients receiving hydromorphone. According to Fresenius Kabi, a MicroVault labeled as morphine sulfate injection 2 mg/1 mL may contain a prefilled syringe of Dilaudid (hydromorphone hydrochloride) 0.5 mg/0.5 mL.

A [recall notice](https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/fresenius-kabi-issues-voluntary-nationwide-recall-one-lot-morphine-sulfate-injection-usp-simplistr?utm%5Fmedium=email&utm%5Fsource=govdelivery) says that the use of the mislabeled product could result in serious or life-threatening adverse health consequences, including respiratory depression and death. Patients at greatest risk include those who are not regularly exposed to opioids, individuals with underlying respiratory disease, pediatric patients, and patients receiving other central nervous system depressants, Fresenius Kabi said.